ALNY vs. SNY
Compare and contrast key facts about Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi (SNY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: ALNY or SNY.
Correlation
The correlation between ALNY and SNY is 0.48, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
ALNY vs. SNY - Performance Comparison
Key characteristics
ALNY:
1.27
SNY:
0.30
ALNY:
2.42
SNY:
0.76
ALNY:
1.31
SNY:
1.09
ALNY:
1.81
SNY:
0.45
ALNY:
5.78
SNY:
1.01
ALNY:
12.26%
SNY:
9.53%
ALNY:
55.42%
SNY:
24.09%
ALNY:
-83.58%
SNY:
-46.65%
ALNY:
-14.04%
SNY:
-12.27%
Fundamentals
ALNY:
$33.57B
SNY:
$135.07B
ALNY:
-$2.10
SNY:
$2.82
ALNY:
-0.49
SNY:
0.88
ALNY:
14.69
SNY:
2.99
ALNY:
507.84
SNY:
1.61
ALNY:
$2.35B
SNY:
$43.77B
ALNY:
$2.02B
SNY:
$31.14B
ALNY:
-$152.67M
SNY:
$10.09B
Returns By Period
In the year-to-date period, ALNY achieves a 9.79% return, which is significantly higher than SNY's 8.09% return. Over the past 10 years, ALNY has outperformed SNY with an annualized return of 8.59%, while SNY has yielded a comparatively lower 4.20% annualized return.
ALNY
9.79%
15.17%
-5.10%
69.64%
13.72%
8.59%
SNY
8.09%
4.55%
0.77%
8.46%
4.85%
4.20%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
ALNY vs. SNY — Risk-Adjusted Performance Rank
ALNY
SNY
ALNY vs. SNY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi (SNY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
ALNY vs. SNY - Dividend Comparison
ALNY has not paid dividends to shareholders, while SNY's dividend yield for the trailing twelve months is around 8.15%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ALNY Alnylam Pharmaceuticals, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
SNY Sanofi | 8.15% | 4.22% | 3.83% | 4.22% | 3.80% | 3.61% | 3.46% | 4.29% | 3.67% | 4.03% | 3.79% | 4.19% |
Drawdowns
ALNY vs. SNY - Drawdown Comparison
The maximum ALNY drawdown since its inception was -83.58%, which is greater than SNY's maximum drawdown of -46.65%. Use the drawdown chart below to compare losses from any high point for ALNY and SNY. For additional features, visit the drawdowns tool.
Volatility
ALNY vs. SNY - Volatility Comparison
Alnylam Pharmaceuticals, Inc. (ALNY) has a higher volatility of 15.15% compared to Sanofi (SNY) at 8.79%. This indicates that ALNY's price experiences larger fluctuations and is considered to be riskier than SNY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
ALNY vs. SNY - Financials Comparison
This section allows you to compare key financial metrics between Alnylam Pharmaceuticals, Inc. and Sanofi. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ALNY vs. SNY - Profitability Comparison
ALNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Alnylam Pharmaceuticals, Inc. reported a gross profit of 523.15M and revenue of 594.19M. Therefore, the gross margin over that period was 88.0%.
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sanofi reported a gross profit of 7.72B and revenue of 10.61B. Therefore, the gross margin over that period was 72.8%.
ALNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Alnylam Pharmaceuticals, Inc. reported an operating income of 18.08M and revenue of 594.19M, resulting in an operating margin of 3.0%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sanofi reported an operating income of 2.29B and revenue of 10.61B, resulting in an operating margin of 21.5%.
ALNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Alnylam Pharmaceuticals, Inc. reported a net income of -57.48M and revenue of 594.19M, resulting in a net margin of -9.7%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sanofi reported a net income of 1.87B and revenue of 10.61B, resulting in a net margin of 17.7%.